FP
PACB icon

Financial Perspectives’s Pacific Biosciences PACB Stock Holding History

Financial Perspectives’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-162
Closed -$4.14K – 670
2021
Q3 		$4.14K Hold
162
– – ﹤0.01% 539
2021
Q2 		$5.67K Sell
162
-5,234
-97% -$152K ﹤0.01% 522
2021
Q1 		$162K Buy
+5,396
New +$189K 0.01% 423

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Financial Perspectives's PACB Position: Q4 2021 in Review

Financial Perspectives sold out of Pacific Biosciences (PACB) in Q4 2021, closing a stake of 162 shares — an estimated $4.14K sold.

Financial Perspectives first reported a position in PACB in Q1 2021 and held it in 3 quarters. The position peaked at $162K in Q1 2021. 256 funds tracked by Wall St. Rank hold PACB as of Q4 2021.

  • Financial Perspectives reported no remaining Pacific Biosciences position as of Q4 2021 after selling out during the quarter.
  • Financial Perspectives sold 162 Pacific Biosciences shares in Q4 2021, an estimated $4.14K.
  • Financial Perspectives first reported a position in Pacific Biosciences in Q1 2021 and held it in 3 quarters.
  • Financial Perspectives's Pacific Biosciences position peaked at $162K in Q1 2021.
  • 256 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2021.

Based on Financial Perspectives's 13F filing for Q4 2021, filed 10 Jan 2024.